IIT Guwahati, Bose Institute Kolkata create Injectable Hydrogel for localised cancer treatment

Guwahati, Jan. 3: In a multi-institutional research project led by researchers from the Indian Institute of Technology (IIT) Guwahati and the Bose Institute Kolkata, an advanced injectable hydrogel has been developed for localised cancer treatment.

This innovative hydrogel-based therapy delivers anti-cancer drugs directly to tumour sites, significantly reducing the side effects typically associated with conventional cancer treatments.

The findings of the research have been published in Materials Horizons, a journal of the Royal Society of Chemistry. The paper is co-authored by Prof Debapratim Das of the Department of Chemistry, along with his research scholars Tanushree Das and Ritvika Kushwaha from IIT Guwahati, and collaborators Dr Kuldip Jana, Satyajit Halder, and Anup Kumar Misra from Bose Institute Kolkata.

"Cancer continues to be a pressing global health challenge, with millions of patients affected world-wide. Current treatments, such as chemotherapy and surgical interventions, often have severe limitations. Surgical removal of tumours is sometimes not feasible, particularly for internal organs, while chemotherapy's systemic delivery often results in harmful side effects by affecting both cancerous and healthy cells," Prof Das said.

The researchers addressed these challenges by designing a hydrogel that delivers drugs precisely to the tumour site, ensuring localized action.

Hydrogels are water-based, three-dimensional polymer networks capable of absorbing and retaining fluids. Their unique structure mimics living tissues, making them suitable for biomedical applications.

This newly developed hydrogel acts as a stable reservoir for anti-cancer drugs and releases them in a controlled manner, responding to specific conditions in the tumour microenvironment.

The hydrogel, composed of ultra-short peptides - biocompatible and biodegradable building blocks of proteins is designed to remain insoluble in biological fluids, ensuring it stays localized at the injection site. It responds to elevated glutathione (GSH) levels, a molecule abundant in tumour cells.

Upon encountering high GSH levels, the hydrogel triggers a controlled drug release directly into the tumour, minimizing its interaction with healthy tissues and reducing systemic side effects.

"This work exemplifies how scientific innovation can directly address the pressing needs of cancer treatment. The hydrogel's unique properties allow it to work in harmony with the biological environment, offering precision where it is needed most. We are excited by its potential to transform our thoughts about localized drug delivery," Prof Das said.

In preclinical trials on a murine model of breast cancer, the hydrogel showcased high efficacy.

A single injection of the hydrogel, loaded with the chemotherapy drug Doxorubicin, resulted in a 75 per cent reduction in tumour size within 18 days. Crucially, the hydrogel remained localized at the tumour site, steadily releasing the drug over time without causing detectable side effects on other organs.

"This innovative delivery system enhances the drug's effectiveness while reducing the required dosage, thus minimizing toxicity. Laboratory studies further demonstrated that the hydrogel improves drug uptake by cancer cells, induces cell cycle arrest, and promotes programmed cell death, thereby attacking tumours on multiple fronts. Further studies are going on to find out the maximum amount of reduction in the size of the tumour by a single dose. Moreover, we are also looking into other types of tumours. Once all the studies are complete, we will apply to take the material for clinical trials and are looking for an appropriate partner to do the same," Prof Das said.

- By Staff Reporter